$BBOT News
Last published 1d ago
- 1d agoBBOTBridgeBio Oncology Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoBBOTBBOT Reports Third Quarter 2026 Financial Results and Update on Corporate ProgressGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the quarter ended September 30, 2026, and provided a business update.
- 1mo agoBBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 2mo agoBBOTBBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant CancersGlobeNewswireBBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly competitive ORR in the 2L+
- 2mo agoBBOTBBOT to Participate in Upcoming Investor Healthcare ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies,
- 3mo agoBBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 6mo agoBBOTBBOT Reports First Quarter 2026 Financial Results and Update on Corporate ProgressGlobeNewswireAnnounced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and
- 6mo agoBBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 6mo agoBBOTBBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026GlobeNewswireBBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines BBO-11818 demonstrates robust
- 6mo agoBBOTBBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive ChairmanGlobeNewswirePedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and
- 6mo agoBBOTBBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026GlobeNewswireBBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia BBO-10203
- 6mo agoBBOTBBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal AdenocarcinomaGlobeNewswireBBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected in the second half
- 7mo agoBBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 8mo agoBBOTBBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS InhibitorGlobeNewswireBBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical
- 8mo agoBBOTHLXBBBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate ProgressGlobeNewswireBBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy
- 9mo agoBBOTBBOT to Participate in Upcoming Investor Healthcare ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 9mo agoBBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 10mo agoBBOTBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 10mo agoBBOTBBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline ProgramsGlobeNewswireBBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month
- 11mo agoBBOTBBOT to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 11mo agoBBOTBBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 11mo agoBBOTBBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)GlobeNewswirePreclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows robust anti-tumor activity both as monotherapy and
- 11mo agoBBOTBBOT to Participate in Upcoming December Investor Healthcare ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 12mo agoBBOTHLXBBBOT Reports Third Quarter 2025 Financial Results and Update on Corporate ProgressGlobeNewswireBBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced
- 1y agoBBOTBBOT to Participate in the Jefferies Global Healthcare Conference in LondonGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 1y agoBBOTBBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 1y agoBBOTPreclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing HyperglycemiaGlobeNewswireData demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monotherapy activity, as well as combination activity with
- 1y agoBBOTBBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswireData demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRASG12D and KRASG12V cell-derived xenograft (CDX) modelsBBO-11818's
- 1y agoBBOTBBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 1y agoBBOTBBOT to Participate in Upcoming September Investor Healthcare ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today
- 1y agoBBOTHLXBBBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K InhibitionGlobeNewswireBusiness combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million